首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes
【24h】

Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes

机译:肺炎球菌社区获得性肺炎的肺部并发症:发生率,预测因素和结果

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to evaluate the clinical characteristics, predictors and outcomes of pneumococcal pneumonia developing pulmonary complications and the distribution of pneumococcal serotypes. It was a prospective study including all adult patients admitted to the Hospital Clinic of Barcelona, Spain (2001-2009) with the diagnosis of pneumococcal pneumonia. Microbiological investigation was systematically performed, including antimicrobial susceptibility and serotype distribution (only invasive strains isolated during 2006-2009). Complicated pneumonia was defined as the presence of one or more pulmonary complications: pleural effusion, empyema, or multilobar infiltrates. We included 626 patients, and 235 (38%) had the following pulmonary complications: pleural effusion, 122 (52%); empyema, 18 (8%); and multilobar infiltration, 151 (64%). Forty-six (20%) patients had more than one complication. Patients with pulmonary complications showed a higher rate of intensive-care unit admission (34% vs. 13%, p<0.001), a higher rate of shock (16% vs. 7%, p<0.001), a longer length of stay (9 days vs. 6 days, p<0.001), and a lower rate of penicillin resistance (14% vs. 25%, p0.013), but similar mortality (9% vs. 8%). No significant differences were observed in the serotype distribution between complicated and uncomplicated pneumonia. Chronic obstructive pulmonary disease (COPD) (OR 0.38, 95% CI 0.23-0.63; p<0.001) was a protective factor against pulmonary complications, whereas chronic liver disease (OR 3.60, 95% CI 1.71-7.60; p0.001), admission C-reactive protein level ≥18mg/dL (OR 2.77, 95% CI 1.91-4.00; p<0.001) and admission creatinine level >1.5mg/dL (OR 2.01, 95% CI 1.31-3.08; p0.001) were risk factors for pulmonary complications. Complicated pneumonia was characterized by a more severe clinical presentation, but was not associated with increased mortality. Resistance to antibiotics was lower in complicated cases. No significant differences were observed in the serotype distribution between complicated and uncomplicated pneumonia. In the multivariate analysis, COPD was a protective factor against pulmonary complications.
机译:这项研究的目的是评估肺炎球菌性肺炎发展为肺部并发症和肺炎球菌血清型分布的临床特征,预测因素和结果。这是一项前瞻性研究,包括西班牙巴塞罗那医院(2001-2009年)住院的所有诊断为肺炎球菌性肺炎的成年患者。系统地进行了微生物学调查,包括抗菌素敏感性和血清型分布(仅在2006-2009年间分离出侵入性菌株)。并发肺炎定义为存在一种或多种肺部并发症:胸腔积液,脓胸或多叶浸润。我们纳入626例患者,其中235例(38%)患有以下肺部并发症:胸腔积液122例(52%);脓胸,18(8%);多叶浸润151(64%)。四十六(20%)例患者发生了一种以上的并发症。肺部并发症患者的重症监护病房住院率更高(34%vs. 13%,p <0.001),休克发生率更高(16%vs. 7%,p <0.001),住院时间更长(9天vs. 6天,p <0.001),青霉素耐药率较低(14%vs. 25%,p0.013),但死亡率相似(9%vs. 8%)。复杂性肺炎和非复杂性肺炎的血清型分布没有明显差异。慢性阻塞性肺疾病(COPD)(OR 0.38,95%CI 0.23-0.63; p <0.001)是预防肺部并发症的保护因素,而慢性肝病(OR 3.60,95%CI 1.71-7.60; p0.001),入院C反应蛋白水平≥18mg / dL(OR 2.77,95%CI 1.91-4.00; p <0.001)和入院肌酐水平> 1.5mg / dL(OR 2.01,95%CI 1.31-3.08; p0.001)肺部并发症的危险因素。复杂性肺炎的特点是临床表现更为严重,但与死亡率增加无关。在复杂情况下,对抗生素的抵抗力较低。复杂性肺炎和非复杂性肺炎的血清型分布没有明显差异。在多变量分析中,COPD是预防肺部并发症的保护因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号